山東博安生物技術股份有限公司

山東博安生物技術股份有限公司 is a legitimate registered non-Hong Kong company duly registered under Part 16 of the Companies Ordinance (Cap. 622) of Hong Kong on 2022-03-28 (operating for 4 years). According to the official register of the Hong Kong Companies Registry (CR), the entity holds an active statutory status of [Live / In Operation] (Statutory records last verified: November 2026).

Official Hong Kong government registers assign two statutory identifiers to 山東博安生物技術股份有限公司: 1. Business Registration Number (BRN / UBI): [73899810] (statutory identifier for tax and commercial registration under Cap. 310); 2. Company Registration Number (CRN): [F0030432] (statutory filing number under Cap. 622). Commercial counterparties should verify both numbers on contracts and invoices.

In Hong Kong corporate compliance and banking KYC due diligence, verifying the decision-makers of 山東博安生物技術股份有限公司 requires cross-checking three statutory filings: 1. Latest Annual Return (Form NAR1) for issued share capital and shareholder equity percentages; 2. Form ND2A (Notice of Change of Company Secretary and Director) for interim board changes after the annual return date; and 3. Significant Controllers Register (SCR) penetration for natural persons or holding entities exercising ultimate control (UBO).

Yes. According to the official statutory records of the Hong Kong Companies Registry, 山東博安生物技術股份有限公司 has officially recorded 1 legal name change(s): [山東博安生物技術股份有限公司 (effective 2022-03-28)]. Pursuant to Sections 107 and 109 of the Companies Ordinance (Cap. 622), each name change was passed by special resolution (Form NNC2) and took statutory effect upon issuance of a Certificate of Change of Name by the Registrar of Companies; under Section 109(4), changing the company name does not affect any rights, obligations, or legal proceedings of the company.

Yes. Official filing registers of the Hong Kong Companies Registry confirm that 山東博安生物技術股份有限公司 has statutory filings on official record (latest statutory filing indexed on 2026-05-05: Form NAR1 - Annual Return (2026) (Chinese)). Pursuant to Part 16 (Section 788) of the Companies Ordinance (Cap. 622), registered non-Hong Kong companies must deliver an Annual Return (Form NN3) to the Registrar of Companies within 42 days after each registration anniversary. Available verified original dossiers include: latest Annual Return of Non-Hong Kong Company (Form NN3 - detailing principal place of business in Hong Kong and authorised representatives), Application for Registration (Form NN1), Constitutive Documents, and Change of Secretary/Director/Authorised Representative notices (Form NN7 / NN8C), all carrying official ICRIS barcode verification.

According to multi-dimensional checks across Hong Kong statutory authorities: 1. Regulatory Licences: Officially licensed by Hong Kong statutory authorities, currently holding: Statutory Authority (Hkex) (Licence No. 06955); 2. Judicial Screening (Litigation & Winding-Up): screened against Hong Kong Judiciary cause books and winding-up registers under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32), with zero public compulsory winding-up petitions (HCCW) or civil litigation dockets currently indexed.

The principal place of business in Hong Kong of 山東博安生物技術股份有限公司 on official record is situated at: [Unit 1918, 19/F, Lee Garden One, Causeway Bay, Hong Kong]. Official registry dossiers also record 1 statutory registered office address change filing(s) (Form NR1). Pursuant to Part 16 (Section 791) of the Companies Ordinance (Cap. 622), all registered non-Hong Kong companies must maintain a principal place of business in Hong Kong and notify the Registrar within 15 days of any change (Form NN9) for the lawful service of statutory notices and court process.

Before entering into cross-border trade, credit settlement, or joint venture agreements with 山東博安生物技術股份有限公司 (CRN: F0030432 / 8-digit BRN: 73899810), standard institutional due diligence under Hong Kong law comprises four core verifications: 1. Standing & Identifier Match: Cross-checking active status under Cap. 622 and its 8-digit BRN under Cap. 310; 2. Equity & Signatory Penetration: Inspecting the latest Annual Return (Form NAR1) and Form ND2A to verify paid-up share capital, shareholders, and authorized signatory directors; 3. Register of Charges Screening: Checking Form NM1 filings under Part 8 (Section 334) of Cap. 622 for pledged corporate assets or bank floating charges; and 4. Judicial Screening: Verifying the absence of High Court winding-up petitions (HCCW) or civil litigation writs.